Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2022 - 2025)

Zentalis Pharmaceuticals has reported Income from Continuing Operations over the past 4 years, most recently at 35216000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 35216000.0 for Q4 2025, up 25.82% from a year ago — trailing twelve months through Dec 2025 was 137060000.0 (up 17.37% YoY), and the annual figure for FY2025 was 137060000.0, up 17.37%.
  • Income from Continuing Operations for Q4 2025 was 35216000.0 at Zentalis Pharmaceuticals, down from 26691000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ZNTL hit a ceiling of 10040000.0 in Q1 2024 and a floor of 98860000.0 in Q2 2023.
  • Median Income from Continuing Operations over the past 4 years was 50204000.0 (2022), compared with a mean of 50003062.5.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 116.47% in 2024 and later tumbled 580.87% in 2025.
  • Zentalis Pharmaceuticals' Income from Continuing Operations stood at 48162000.0 in 2022, then fell by 26.53% to 60939000.0 in 2023, then increased by 22.1% to 47472000.0 in 2024, then grew by 25.82% to 35216000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 35216000.0 (Q4 2025), 26691000.0 (Q3 2025), and 26874000.0 (Q2 2025) per Business Quant data.